The myPath Test for Melanoma
Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma
Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma.
Clinical Pearls:
- There are approximately 1.5 million biopsies done in the United States each year for atypical moles in an effort to exclude the possibility of melanoma.
- Approximately 15% of these biopsies are difficult to diagnose.
- The myPath test is objective and produces a single score that can help differentiate malignant melanoma from a benign nevus.
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
